Market Research Logo

Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights, 2018-2028

Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights, 2018-2028

INTRODUCTION
Parkinson’s disease is a chronic disorder that gradually leads to progressive deterioration of motor functions due to loss of dopamine-producing brain cells. It is presently the second most common neurodegenerative disease (after Alzheimer’s disease) and is characterized by symptoms such as shaking, rigidity, difficulty in walking / movement, and several other cognitive and behavioral problems. Parkinson’s disease is known to affect 1-2 per 1,000 individuals and has been shown to impact approximately 1% of the population aged above 60 years. It is also worth highlighting that, every year, nearly 60,000 Americans are diagnosed with Parkinson’s. The disease has been estimated to incur combined direct and indirect costs of close to USD 25 billion in the US annually. With increasing disease prevalence and the corresponding growth in socioeconomic burden, the field faces a pressing need for accurate diagnostic (predictive) tests, and efficient treatment options for slowing the progression of the disease. Despite the availability of several types of dopamine agonists, there still are a myriad of motor and non-motor symptoms that currently available therapies are unable to treat.

The unavailability of neuroprotective therapies remains one of the prime unmet needs in this domain. The disease is highly complex and is known to render any single therapeutic approach inadequate to deal with its multifaceted etiopathogenesis. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease modifying pharmacological interventions, therapies to offer symptomatic relief and drugs to try to cure the disease as well. In fact, there are multiple initiatives established by start-ups that are being backed by venture capital funding to expedite the development of potential therapeutic options for better disease management.

SCOPE OF THE REPORT
The “Parkinson’s Disease Market: Pipeline Review, Developer Landscape and Competitive Insights, 2018-2028” report provides an extensive study on the marketed, clinical and preclinical molecules being investigated for the treatment of Parkinson’s disease. Figure 1.1 summarizes the scope of the report and the specific modules that have been covered in extensive detail.

Amongst other elements, the report includes:
A detailed assessment of the current market landscape of drugs being developed for the treatment of Parkinson’s disease, providing information on drug developer(s), phase of development (clinical, preclinical / discovery stage) of product candidates, type of molecule (small molecule, biologic or gene / cell therapy), treatment type (disease modifying agent, drugs offering symptomatic relief or drugs for curing the disease), mechanism of action, and route of administration.

An in-depth an alysis of the product pipeline and developer companies, featuring four schematic representations; these include [A] a heptagon representation highlighting the distribution of the marketed and development stage molecules based on their mechanisms of action, [B] a 2X2 grid analysis, representing the distribution of drug candidates across various molecule types and stages of development, [C] a funnel analysis highlighting the distribution of molecules (segregated by stage of development) based on route of administration and treatment type, and [D] a logo landscape of the various industry players involved in the development of drugs, distributed on the basis of location of headquarters and company size (small-sized, mid-sized and large).

An analysis highlighting the key unmet needs across Parkinson’s disease, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, patient blogs and the views of key opinion leaders expressed on online platforms.

Comprehensive profiles of drugs in phase III of clinical development, with information on the developer, specific target patient population, mechanism of action, clinical trials, current status of development, and recent developments (if available).

An insightful competitive analysis, highlighting the key players in the domain on the basis of the strength of their development portfolio. For all companies that emerged as important players in this field, we have presented a five-dimensional spider web analysis, taking into account the company’s size, activity on Google Trends, stage of development of lead molecule, strength of the Parkinson’s disease pipeline and the (present) number of clinical trials being conducted by the player.

A detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired in the last few years, along with the geographical distribution of this activity. The analysis features an ownership change matrix and presents a financial evaluation of these deals (revenues and respective deal multiples) as well.

A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers involved in the development of molecules in this domain.

An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.

A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in development of anti-Parkinson’s therapeutics.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered from both secondary and primary sources. The opinions and insights presented in this study were influenced by inputs (through a comprehensive survey) of several key players in this domain. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. The analysis of content presented on informal (50 patient blogs and over 12,000 social media posts) and formal (over 200 scientific literature studies) literary sources, and the opinions express by industry experts confirm the existence of a significant unmet need within the anti-Parkinson’s disease therapeutics market. Some of the unaddressed concerns suggested through multiple portals include lack of disease modifying treatments, delayed diagnosis, unavailability of therapies to manage non-motor symptoms and poor quality of life.

2. Over 180 product candidates are currently being evaluated across various stages of development for the management / treatment of Parkinson’s disease. Of these, 55% are in the preclinical or discovery phase. Amongst the drugs that are under clinical development, 7 are in phase III, 42 in phase II, and 25 in phase I and phase I/II trials. Interestingly, since 2015, four product candidates have been approved; these are (based on year of approval) OSMOLEX ER™ (2018), NUPLAZID® (2016), ONGENTYS® (2016) and Xadago® (2015).

3. Majority of novel drugs (53%) are disease modifying agents, while 32% of candidate molecules are being developed for providing symptomatic relief only. Rest of the drugs are designed and being evaluated to cure Parkinson’s disease. It is worth highlighting that 34% of pipeline candidates have been shown to induce therapeutic effect by inhibiting a protein / enzyme; further, 17% are dopamine agonists, while 13% are channel / receptor antagonists.

4. The market landscape is characterized by the presence of large (20), mid-sized (31) and small-sized companies (91). Some of the prominent large companies engaged in this domain include (in alphabetical order, no selection criteria) AbbVie, ACADIA Pharmaceuticals, Amgen, AstraZeneca, BIAL Group, Eli Lilly, Lundbeck, Luye Pharmaceuticals, Osmotica Pharmaceutical, Sumitomo Dainippon Pharma, UCB Pharma and Zambon. The growing unmet need within this domain has spurred the establishment of many start-ups in the recent years; examples include (in alphabetical order, no selection criteria) 4P Therapeutics, Acelot, Aeolus Pharmaceuticals, Aestas Pharma, Antoxis, BlueRock Therapeutics, BrainStorm Cell Therapeutics, Capo Therapeutics, Cellix Bio, Cerevance, Clera, Contera Pharma, Curemark, DermaXon, Domain Therapeutics, Enterin, Fabre-Kramer Pharmaceuticals, Herantis Pharma Impel NeuroPharma, Io Therapeutics, Junaxo, Living Cell Technologies, Lysosomal Therapeutics, Melior Pharmaceuticals, Minerave Neurosciences, Mission Therapeutics, Peptron, Pharma Two B, Prana Biotechnology, Priavoid, Primary Peptides, QR Pharma, Serina Therapeutics, TechnoPhage, Vivreon Biosciences and Xoc Pharmaceuticals.

5. More than USD 2.2 billion has been invested in various companies, across 182 instances of funding, since 2010. The Michael J. Fox Foundation, Vinnova, Roche Venture Fund, Mérieux Développement, Alliance of Angels, Shire, Ysios Capital, Third Rock Ventures, Takeda Pharmaceutical, Sunstone Capital and Sofinnova Partners have emerged as some of the prominent investors (in terms of number of funding instances) in this market.

6. Several prominent scientists (over 100 investigators evaluated) have made significant contributions in advancing the clinical development efforts and, therefore, have emerged as key opinion leaders in this field. It is worth noting that universities and hospitals, across various regions, have been conducting breakthrough research along with various KOLs to develop an efficient treatment for patients with Parkinson’s disease; examples of these universities and hospitals are (in alphabetical order, no selection criteria) Addenbrookes Hospital, Auckland City Hospital, Cedars-Sinai Medical Center, Jichi Medical University and Loma Linda University of Health.

7. The domain has witnessed over seven acquisitions in the recent past, highlighting that the market is partly driven by acquisition of start-ups with promising drug candidates. These include multiple big-ticket deals; a prominent example being the acquisition of Prexton Therapeutics by Lundbeck (deal valued at USD 1.1 billion) in March 2018. Interestingly, majority of the acquisition events took place in the US; however, there were several cross-border acquisitions involving start-ups based in the US and big pharmaceutical players in Japan.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the Parkinson’s disease market in the long term.

Chapter 3 provides an introduction to Parkinson’s disease. It provides a detailed discussion on the history, symptoms and stages of Parkinson’s disease, factors influencing disease progression and the various treatment regimens that are available in the market. The section also highlights the epidemiology of the disease and its economic burden across various regions.

Chapter 4 includes information on close to 190 molecules that are currently approved / under development for therapeutic use. It features a comprehensive analysis of pipeline molecules, highlighting the phase of development (clinical, preclinical / discovery stage) of product candidates, type of molecule (small molecule, biologic or gene / cell therapy), treatment type (disease modifying agent, drugs offering symptomatic relief or drugs for curing the disease), mechanism of action, and route of administration. In addition, it presents certain key insights derived from the study, which include a heptagon representation highlighting the distribution of the marketed and pipeline molecules based on different mechanisms of action. The chapter includes a comprehensive 2X2 grid analysis, representing the distribution of the drug candidates across various molecule types and stages of development, and a funnel analysis highlighting the distribution of molecules on the basis of stage of development, route of administration and treatment type. Additionally, the chapter features a logo landscape of developers engaged in this domain, distributed on the basis of location of headquarters and size of the company.

Chapter 5 highlights the key unmet needs associated with the management and treatment of Parkinson’s disease. The chapter provides detailed analysis of unmet needs that were identified from views expressed by patients / experts across different platforms, such as social media posts, recent publications and patient blogs, and the inputs of key opinion leaders at conferences / symposiums. The chapter presents an insightful sentiment analysis and word cloud analysis, summarizing the opinions expressed across the public portals.

Chapter 6 contains detailed profiles of drugs that are in phase III of clinical development. Each profile features an overview of the developer, and provides information on the status of development, target population, mechanism of action, results of clinical trials (if available) and recent developments (if available).

Chapter 7 features an insightful competitive analysis, highlighting the most active players in this domain on the basis of their activity (in terms of developing therapeutics for Parkinson’s disease). For each of the shortlisted companies, we have presented a spider web analysis highlighting the company’s size, activity on Google, stage of development of lead molecule, strength of the Parkinson’s disease pipeline and the (present) number of clinical trials being conducted by the player.

Chapter 8 presents a detailed analysis of the mergers and acquisitions that have taken place in this industry. The chapter provides information on the acquiring and acquired companies (headquarters and the ownership (public / private)), along with the year of acquisition, acquiring amount (if available), and the financial status of the acquired company at the time of acquisition. It features a detailed ownership change matrix depicting the distribution of mergers and acquisitions across private firms, public firms and sole proprietorships. It also includes an evaluation of the financials of these deals (revenues of the acquired firms at the time of acquisition and their respective deal multiples).

Chapter 9 provides an analysis of KOLs in the field of Parkinson’s disease. It features a comprehensive list of principal investigators of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also features a comparative analysis, highlighting those KOLs who have relatively more experience in this domain.

Chapter 10 presents details on various investments received by companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place amongst the start-ups in the period between 2010 and March 2018, highlighting the growing interest of the venture capital community and other strategic investors in this market.

Chapter 11 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in development of therapeutics for Parkinson’s disease. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 13 is an appendix, which contains the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
APPENDIX 2: LIST OF COMPANIES
The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. 3M New Ventures
2. 4P Therapeutics
3. 5AM Ventures
4. Abbott
5. AbbVie
6. AC Immune
7. ACADIA Pharmaceuticals
8. Accera
9. Acelot
10. Acino
11. Acorda Therapeutics
12. Addenbrooke's Hospital
13. Addex Therapeutics
14. Aeolus Pharmaceuticals
15. Aestas Pharma
16. AFFiRiS
17. Alliance of Angels
18. AMAbiotics
19. Amarantus BioScience
20. Amgen
21. aMoon
22. Anavex Life Sciences
23. Antoxis
24. ApoPharma
25. Araclon Biotech
26. ArmaGen
27. Armistice Capital
28. Arrien Pharmaceuticals
29. Asceneuron
30. AstraZeneca
31. Atlas Venture
32. Auckland City Hospital
33. Avanir Pharmaceuticals
34. Avant Diagnostics
35. Axovant Sciences
36. AZTherapies
37. Azur Pharma
38. Babraham Research Campus
39. Bayer
40. Ben Franklin Technology Partners
41. BenevolentAI
42. Bertin Bioreagent
43. BIAL
44. BioAdvance
45. BioArctic
46. BioElectron Technology
47. Biogen
48. BioReference Laboratories
49. Biotie Therapeutics
50. BlueRock Therapeutics
51. Boehringer Ingelheim Venture Fund
52. Bpifrance
53. BrainStorm Cell Therapeutics
54. BrainX
55. Britannia Pharmaceuticals
56. Brookside Capital
57. Bukwang Pharmaceutical
58. Burkina Faso Caisses Populaires
59. BVF Partners
60. Caixa Capital Risc
61. Callaghan Innovation
62. Canadian Institutes of Health Research
63. Cantabio Pharmaceuticals
64. Capo Therapeutics
65. Carna Biosciences
66. Casdin Capital
67. Cedars-Sinai Medical Center
68. Celavie Biosciences
69. Celerion
70. Cellix Bio
71. Centurion Private
72. Cerevance
73. Chelsea Therapeutics
74. Chinese Academy of Sciences
75. Chipscreen Biosciences
76. Clera
77. CleveXel Pharma
78. Clinical Research Services Turku
79. Cobra Biologics
80. Collaborative Medicinal Development
81. Collidion
82. Columbia University Irving Medical Center
83. Commission for Technology and Innovation
84. Contera Pharma
85. Corium
86. Cormorant Asset Management
87. Crossroad FCP
88. Curemark
89. Cynapsus Therapeutics
90. Dart NeuroScience
91. Dementia Discovery Fund
92. Denali Therapeutics
93. DermaXon
94. Desitin Arzneimittel
95. Deutsche Parkinson Vereinigung
96. Discover Growth Fund
97. Domain Therapeutics
98. Dominion Capital
99. Dong-A ST
100. Duke University Health Center
101. Eli Lilly
102. Emory University
103. Enterin
104. Fabre-Kramer Pharmaceuticals
105. Federal University of São Paulo
106. Forbion Capital Partners
107. Friedrich-Baur-Institute
108. Fulcrum Therapeutics
109. Gabriel Capital Management
110. Gene Therapy Research Institution
111. Generali Financial Holdings
112. Genervon Biopharmaceuticals
113. Genomia
114. GlaxoSmithKline
115. GNT Pharma
116. Grampian Biopartners
117. Hammersmith Medicines Research
118. Hatteras Venture Partners
119. HealthEquity
120. Henri Mondor Hospital
121. Henry Ford West Bloomfield Hospital
122. Herantis Pharma
123. Hercules Capital
124. Herculis Partners
125. Highland Capital Management
126. Histostem
127. Hôpital Pitié-Salpêtrière
128. Horizon Technology Finance
129. Hospital Angeles Pedregal
130. Hospital Sant Pau
131. Hypnion
132. Idec Pharmaceuticals
133. IIB Sant Pau
134. Immungenetics
135. IMPAX Laboratories
136. Impel NeuroPharma
137. Imperial Innovations
138. Index Ventures
139. Inhibikase Therapeutics
140. Innovate UK
141. Innovative California Biosciences International
142. Intec Pharma
143. Integrative Research Laboratories
144. International Infusion
145. International Stem Cell Corporation
146. Intra-Cellular Therapies
147. Invercaria
148. Io Therapeutics
149. IRCCS Ospedale San Raffaele
150. Israel Biotech Fund
151. Israel Innovation Authority
152. Jazz Pharmaceuticals
153. JEIL Pharmaceutical
154. Jichi Medical University
155. JK&B Capital
156. Johns Hopkins University
157. Johnson & Johnson
158. Junaxo
159. Kainos Medicine
160. Kapital Assets
161. Khondrion
162. KISSEI Pharmaceutical
163. Korea Drug Development Fund
164. K-PAX Pharmaceuticals
165. Kyowa Hakko Kirin
166. Lightstone Ventures
167. Lincoln Park Capital Fund
168. Living Cell Technologies
169. Loma Linda University Health
170. Longevity Biotech
171. LTS Lohmann Therapie-Systeme
172. Luc Therapeutics
173. Lundbeck
174. Luye Pharma Group
175. Lysosomal Therapeutics
176. MedGenesis Therapeutix
177. Medical University of Innsbruck
178. Med-Life Discoveries
179. Melbourne Health
180. Melior Pharmaceuticals
181. Merck Ventures
182. Mérieux Développement
183. Mertz Holdings
184. Metabolic Solutions Development
185. MIG Verwaltungs
186. Minerva Neurosciences
187. Ministry of Health (Brazil)
188. Mission Therapeutics
189. Mitochon Pharmaceuticals
190. Mitsubishi Tanabe Pharma
191. Mitsui Global Investment
192. Montisera
193. MS Ventures
194. National Institute of Mental Health
195. National Institute of Neurological Disorders and Stroke
196. National Institutes of Health
197. National Science Foundation
198. Netherlands Translational Research Center
199. Neurocrine Biosciences
200. NeuroDerm
201. Neurodyn
202. NeuroGeneration
203. NeuroHealing Pharmaceuticals
204. Neurolixis
205. NeuroNascent
206. NeurOp
207. Neuropore Therapies
208. New World Laboratories
209. Newron Pharmaceuticals
210. NewYork-Presbyterian Hospital
211. Nice & Green
212. nLife Therapeutics
213. NLS Pharma
214. Nordic Life Sciences
215. Novartis
216. Novo Holdings
217. Nutriband
218. NYU Langone Health
219. Oncodesign
220. OPKO Health
221. Oregon Health and Science University
222. Orion
223. Osmotica Pharmaceutical
224. Otsuka Pharmaceuticals
225. Oulu Deaconess Institute
226. Oxalys Pharmaceuticals
227. Oxford BioMedica
228. Partner Fund Management
229. Partners Innovation Fund
230. Peptron
231. Perceptive Advisors
232. Pfizer Venture Investment
233. Pharma Two B
234. Pharnext
235. Plex Pharmaceuticals
236. Plymouth University Peninsula Schools of Medicine and Dentistry
237. Prana Biotechnology
238. Prexton Therapeutics
239. Priavoid
240. Primary Peptides
241. ProbeX
242. Proclara Biosciences
243. ProMIS Neurosciences
244. Promius Pharma
245. Prothena Biosciences
246. QR Pharma
247. Quintiles Transnational
248. RaQualia Pharma
249. Regis Duffy BioScience Fund
250. reMYND
251. Retrotope
252. Roche
253. Rush University Medical Center
254. SAGE Therapeutics
255. SalubRx Therapeutics
256. Saniona
257. Sanofi
258. Santo Venture Capital
259. Scottish Enterprise
260. Seeds Capital
261. Seoul National University Hospital
262. Serina Therapeutics
263. Seroba Life Science
264. Seventure Partners
265. Shire
266. SK Biopharmaceuticals
267. Sodiv
268. Sofinnova Partners
269. Solstice Neurosciences
270. Sphera Global Healthcare Fund
271. SR One
272. STADA Arzneimittel
273. StrataGent Life Sciences
274. Sumitomo Dainippon Pharma
275. Sun Pharma Advanced Research Company
276. Sunovion
277. Sunstone Capital
278. Swedish Research Council
279. Syntonix Pharmaceuticals
280. Takeda Pharmaceutical
281. TauRx Therapeutics
282. TechnoPhage
283. Teikoku Pharma USA
284. Tekes
285. Teva Pharmaceutical
286. The Michael J. Fox Foundation
287. Theranostics Health
288. Theravance Biopharma
289. Thiel Foundation
290. Third Rock Ventures
291. Titan Pharmaceuticals
292. Toulouse University Hospital
293. Transition Therapeutics
294. Tri-CAP
295. Trigen Holdings
296. Tsinghua University
297. UCB Pharma
298. United Neuroscience
299. University Hospital of Lille
300. University of Aberdeen
301. University of California
302. University of Cologne
303. University of Florida
304. University of Lisbon
305. University of Miami
306. University of Nebraska
307. University of Puerto Rico
308. University of South Florida
309. University of Tübingen
310. University of Western Ontario
311. University of Zurich
312. Uppsala University
313. US WorldMeds
314. V ClinBio
315. venBio
316. Versant Ventures
317. Vertical Pharmaceuticals
318. Victor Company of Japan
319. Vinnova
320. Vivo Capital
321. Vivreon Biosciences
322. Voyager Therapeutics
323. Wellington Management
324. Woodford Patient Capital Trust
325. XenoPort
326. Xoc Pharmaceuticals
327. Yorkville Advisors
328. Ysios Capital
329. Zambon


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. An Overview of Parkinson’s Disease
3.1.1. History and Causes
3.1.2. Symptoms
3.1.3. Epidemiology
3.1.4. Economic Burden
3.2. Parkinson’s Disease Management
3.2.1. Pharmacological Management of Parkinson’s Disease
3.2.2. Non-Pharmacological Management of Parkinson’s Disease
3.2.3. Management of Parkinson’s Disease Using Dietary Supplements
3.2.4. Convenient Remedies to Manage Parkinson’s Disease
4. PIPELINE REVIEW: MARKETED AND DEVELOPMENT DRUGS
4.1. Chapter Overview
4.2. Parkinson’s Disease: Marketed and Development Pipeline
4.3. Parkinson’s Disease: Pipeline Analysis
4.3.1. Distribution by Phase of Development
4.3.2. Distribution by Type of Treatment
4.3.3. Distribution by Type of Molecule
4.3.4. Distribution by Mechanism of Action
4.3.5. Distribution by Route of Administration
4.3.6. Distribution by Leading Players
4.3.7. Funnel Analysis: Distribution by Phase of Development, Treatment Type and Route of Administration
4.3.8. Heptagon Representation: Distribution by Mechanism of Action and Phase of Development
4.3.9. Grid Analysis: Distribution by Type of Molecule and Phase of Development
4.3.10. Developer Logo Landscape: Distribution by Company Size and Location
5. PARKINSON’S DISEASE: UNMET NEED ANALYSIS
5.1. Chapter Overview
5.2. Unmet Need Analysis for Parkinson’s Disease
5.2.1. Analysis Overview
5.2.2. Blogposts by Patients
5.2.2.1. Methodology
5.2.2.2. Affiliated Insights
5.2.3. Published Literature
5.2.3.1. Methodology
5.2.3.2. Affiliated Insights
5.2.4. Social Media Platforms
5.2.4.1. Methodology
5.2.4.2. Affiliated Insights
5.2.5. Expert Opinions
5.2.5.1. Rajesh Pahwa, University of Kansas Medical Center, US
5.2.5.2. V Natarajan, Professor of Neurology, Institute of Neurology, Madras Medical College, India
5.2.5.3. Richard Wade-Martins, Oxford Parkinson’s Disease Center (OPDC) Principal Investigator; Michele Hu, OPDC Clinical Lead; Mark Kelly, OPDC; James Cantley, Department of Physiology, Anatomy and Genetics, University of Oxford, UK
5.2.5.4. K Ray Chaudhuri, Professor of Neurology/Movement Disorders at King's College Hospital, UK
5.2.5.5. Daniel M Cocos, Professor of Physical Therapy & Human Movement Sciences, Feinberg School of Medicine, North-eastern University, US
5.2.5.6. Rachel Dolhun, MD, Neurologist and Movement Disorder Specialist, US
5.2.6. Key Unmet Needs in Parkinson’s Disease
6. DRUG PROFILES: PHASE III MOLECULES
6.1. Chapter Overview
6.2. Drug Profile: Accordion Pill - Carbidopa / Levodopa (Intec Pharma)
6.3. Drug Profile: APL-130277 / Apomorphine Hydrochloride (Sunovion)
6.4. Drug Profile: Apomorphine Hydrochloride (Britannia Pharmaceuticals)
6.5. Drug Profile: Apomorphine Infusion (US WorldMeds)
6.6. Drug Profile: Istradefylline / KW-6002 (Kyowa Hakko Kirin)
6.7. Drug Profile: ND0612 (NeuroDerm)
6.8. Drug Profile: P2B001 (Pharma Two B)
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.2.1. Assumptions and Key Parameters
7.3. Affiliated Insights
7.3.1. Spider Web Competitive Analysis: AbbVie
7.3.2. Spider Web Competitive Analysis: Acorda Therapeutics
7.3.3. Spider Web Competitive Analysis: Addex Therapeutics
7.3.4. Spider Web Competitive Analysis: Axovant Sciences
7.3.5. Spider Web Competitive Analysis: Integrative Research Laboratories
7.3.6. Spider Web Competitive Analysis: Kyowa Hakko Kirin
7.3.7. Spider Web Competitive Analysis: NeuroDerm
7.3.8. Spider Web Competitive Analysis: Sunovion
7.3.9. Spider Web Competitive Analysis: UCB
8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Parkinson’s Disease: Mergers and Acquisitions
8.2.1. Mergers and Acquisitions: Analysis by Year
8.2.2. Mergers and Acquisitions: Geographical Activity
8.2.3. Mergers and Acquisitions: Ownership Change Matrix
8.3. Key Acquisitions: Deal Multiples
9. KOL ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Current Researcher Landscape
9.3.1. Prominent Key Opinion Leaders
9.4. Geographical Location of Key Opinion Leaders
9.5. Most Active Key Opinion Leaders
9.5.1. KOL Profile: Robert Hauser, College of Medicine Neurology
9.5.2. KOL Profile: Mika Scheinin, University of Turku
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Parkinson’s Disease Therapy Developers: Funding and Investment Analysis
10.3.1. Analysis by Cumulative Number of Funding Instances
10.3.2. Analysis by Cumulative Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Most Active Players
10.3.5. Analysis by Most Active Investors
11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Parkinson’s Disease Therapeutics: Phase of Development
11.3. Parkinson’s Disease Therapeutics: Drug Classes
11.4. Parkinson’s Disease Therapeutics: Partnerships
11.5. Parkinson’s Disease Therapeutics: Current Market Opportunity
11.6. Parkinson’s Disease Therapeutics: Future Market Opportunity
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Parkinson’s Disease: Historical Timeline
Figure 3.2 Celebrities Diagnosed with Parkinson’s Disease
Figure 3.3 Parkinson’s Disease: Causal Environmental Factors
Figure 3.4 Parkinson’s Disease: Disease Stages
Figure 3.5 Parkinson’s Disease: Motor Symptoms
Figure 3.6 Parkinson’s Disease: Secondary Symptoms
Figure 3.7 Parkinson’s Disease: Gender-wise Incidence Rates
Figure 3.8 Parkinson’s Disease: Geography-wise Incidence Rates
Figure 3.9 Parkinson’s Disease: Direct and Indirect Costs
Figure 3.10 Parkinson’s Disease Management: Pharmacological Treatment Options
Figure 3.11 Parkinson’s Disease Management: Non-Pharmacological Treatment Options
Figure 3.12 Parkinson’s Disease Management: Surgical Methods
Figure 3.13 Parkinson’s Disease Management: Dietary Supplements
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Treatment
Figure 4.3 Pipeline Analysis: Distribution by Type of Molecule
Figure 4.4 Pipeline Analysis: Distribution by Mechanism of Action
Figure 4.5 Pipeline Analysis: Distribution by Route of Administration
Figure 4.6 Pipeline Analysis: Leading Players
Figure 4.7 Funnel Analysis: Distribution by Type of Treatment, Route of Administration and Development Stage
Figure 4.8 Heptagon Representation: Distribution by Mechanism of Action and Development Stage
Figure 4.9 Grid Analysis: Distribution by Type of Molecule and Development Stage
Figure 4.10 Developer Logo Landscape: Distribution by Size and Location
Figure 5.1 Unmet Need Analysis: Overview of the Methodology
Figure 5.2 Unmet Need Analysis: Word Cloud of Patient Blogs
Figure 5.3 Unmet Need Analysis: Number of Publications, Year-wise Trend
Figure 5.4 Unmet Need Analysis: Needs Highlighted in Published Literature
Figure 5.5 Social Media Analysis: Overview of the Methodology
Figure 5.6 Social Media Analysis: Sentiment Analysis
Figure 5.7 Social Media Analysis: Word Cloud of the Tweets
Figure 5.8 Social Media Analysis: Trends
Figure 5.9 Social Media Analysis: Most Prolific Authors / Contributors
Figure 5.10 Social Media Analysis: Word Clouds highlighting Unmet Needs
Figure 5.11 Social Media Analysis: Celebrities Suffering from Parkinson’s Disease (Word Cloud)
Figure 5.12 Summary of Key Unmet Needs in Parkinson’s Disease
Figure 7.1 Company Competitiveness Analysis: Methodology
Figure 7.2 Company Competitiveness Analysis: Dot-Plot Representation
Figure 7.3 Spider Web Competitive Analysis: AbbVie
Figure 7.4 Spider Web Competitive Analysis: Acorda Therapeutics
Figure 7.5 Spider Web Competitive Analysis: Addex Therapeutics
Figure 7.6 Spider Web Competitive Analysis: Axovant Sciences
Figure 7.7 Spider Web Competitive Analysis: Integrative Research Laboratories
Figure 7.8 Spider Web Competitive Analysis: Kyowa Hakko Kirin
Figure 7.9 Spider Web Competitive Analysis: NeuroDerm
Figure 7.10 Spider Web Competitive Analysis: Sunovion
Figure 7.11 Spider Web Competitive Analysis: UCB
Figure 8.1 Parkinson’s Disease Mergers and Acquisitions: Year-Wise Trend
Figure 8.2 Parkinson’s Disease Mergers and Acquisitions: Geographical Activity
Figure 8.3 Parkinson’s Disease Mergers and Acquisitions: Distribution by International and Local Deals
Figure 8.4 Parkinson’s Disease Mergers and Acquisitions: Ownership Change Matrix
Figure 9.1 KOL Analysis: Overview of Methodology
Figure 9.2 KOL Analysis: Dot-Plot of Principal Investigators
Figure 9.3 KOL Analysis: Geographical Location of Principal Investigators
Figure 9.4 KOL Analysis: Most Active Key Opinion Leaders
Figure 10.1 Parkinson’s Disease Therapy Developers: Cumulative Number of Funding Instances, 2010-2018
Figure 10.2 Parkinson’s Disease Therapy Developers: Distribution of Amount Invested by Year, 2010-2018 (USD Million)
Figure 10.3 Parkinson’s Disease Therapy Developers: Distribution by Type of Funding, 2010-2018
Figure 10.4 Parkinson’s Disease Therapy Developers: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Figure 10.5 Parkinson’s Disease Therapy Developers: Most Active Players by Number of Funding Instances
Figure 10.6 Parkinson’s Disease Therapy Developers: Most Active Investors by Number of Funding Instances
Figure 11.1 Survey Analysis: Distribution by Phase of Development
Figure 11.2 Survey Analysis: Distribution by Drug Classes
Figure 11.3 Survey Analysis: Distribution by Number of Partnerships
Figure 11.4 Survey Analysis: Distribution by Current Market Opportunity
Figure 11.5 Survey Analysis: Distribution by Future Opportunity
LIST OF TABLES
Table 3.1 Parkinson’s Disease Management: Combination Therapies
Table 4.1 Parkinson’s Disease: Marketed and Development Pipeline
Table 6.1 Parkinson’s Disease: Phase III Molecules
Table 6.2 Drug Profile: Accordion Pill – Carbidopa / Levodopa (Intec Pharma)
Table 6.3 Drug Profile: Apomorphine Hydrochloride/ APL-130277 (Sunovion)
Table 6.4 Drug Profile: Apomorphine Hydrochloride (Britannia Pharmaceuticals)
Table 6.5 Drug Profile: Apomorphine Infusion (US WorldMeds)
Table 6.6 Drug Profile: Istradefylline / KW-6002 (Kyowa Hakko Kirin)
Table 6.7 Drug Profile: ND0612 (NeuroDerm)
Table 6.8 Drug Profile: P2B001 (Pharma Two B)
Table 7.1 Parkinson’s Disease Therapy Developer Competitive Analysis: Shortlisted Companies
Table 7.2 Parkinson’s Disease Therapy Developer Competitive Analysis: Spider Web Parameters
Table 8.1 Parkinson’s Disease: Mergers and Acquisitions
Table 8.2 Parkinson’s Disease Acquisitions: Deal Multiples
Table 9.1 KOL Analysis: List of Principal Investigators
Table 9.2 KOL Analysis: Scoring System
Table 9.3 KOL Analysis: List of Universities and Hospitals
Table 9.4 KOL Profile: Robert Hauser, Clinical Trials
Table 9.5 KOL Profile: Robert Hauser, Published Literature
Table 9.6 KOL Profile: Mika Scheinin, Clinical Trials
Table 9.7 KOL Profile: Mika Scheinin, Published Literature
Table 10.1 Parkinson’s Disease Therapy Developers: Funding and Investment Analysis
Table 10.2 Parkinson’s Disease: Summary of Investments
Table 11.1 Survey Respondents: Overview
Table 11.2 Survey Response: Parkinson’s Disease Therapeutics Phase of Development
Table 11.3 Survey Responses: Parkinson’s Disease Therapeutics Drug Classes
Table 11.4 Survey Responses: Parkinson’s Disease Therapeutics Partnerships
Table 11.5 Survey Responses: Parkinson’s Disease Therapeutics Current Market Opportunity
Table 11.6 Survey Responses: Parkinson’s Disease Therapeutics Future Opportunity
Table 12.1 Parkinson’s Disease: Gender-wise Incidence Rates
Table 12.2 Parkinson’s Disease: Direct and Indirect Costs
Table 12.3 Pipeline Analysis: Distribution by Phase of Development
Table 12.4 Pipeline Analysis: Distribution by Type of Treatment
Table 12.5 Pipeline Analysis: Distribution by Type of Molecule
Table 12.6 Pipeline Analysis: Distribution by Mechanism of Action
Table 12.7 Pipeline Analysis: Distribution by Route of Administration
Table 12.8 Pipeline Analysis: Leading Players
Table 12.9 Unmet Needs in Parkinson’s Disease: Number of Publications, Year-wise Trend
Table 12.10 Unmet Needs in Parkinson’s Disease: Unmet Needs Highlighted in Published Literature
Table 12.11 Unmet Needs in Parkinson’s Disease: Social Media Platforms, Sentiment Analysis
Table 12.12 Unmet Needs in Parkinson’s Disease, Social Media Analysis: Most Prolific Authors
Table 12.13 Company Competitiveness Analysis: Dot-Plot Representation
Table 12.14 Spider-Web Analysis: Shortlisted Companies
Table 12.15 Mergers and Acquisitions: Year-Wise Trend
Table 12.16 Mergers and Acquisitions: Geographical Activity
Table 12.17 Mergers and Acquisitions: Distribution by International and Local Acquisitions
Table 12.18 Mergers and Acquisitions: Ownership Change Matrix
Table 12.19 KOL Analysis: Dot-Plot of Principal Investigators
Table 12.20 Parkinson’s Disease Therapeutics Developer: Cumulative Number of Funding Instances, 2010-2018
Table 12.21 Parkinson’s Disease Therapeutics Developer: Distribution of Amount Invested by Year, 2010-2018 (USD Million)
Table 12.22 Parkinson’s Disease Therapeutics Developer: Distribution by Type of Funding, 2010-2018
Table 12.23 Parkinson’s Disease Therapeutics Developer: Distribution of Total Amount Invested by Type of Funding, 2010-2018 (USD Million)
Table 12.24 Parkinson’s Disease Therapeutics Developer: Most Active Players by Number of Funding Instances
Table 12.25 Parkinson’s Disease Therapeutics Developer: Most Active Investors by Number of Funding Instances
Table 12.26 Survey Analysis: Distribution by Phase of Development
Table 12.27 Survey Analysis: Distribution by Drug Classes
Table 12.28 Survey Analysis: Distribution by Number of Partnerships
Table 12.29 Survey Analysis: Distribution by Current Market Opportunity
Table 12.30 Survey Analysis: Distribution by Future Opportunity

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report